Researchers have developed a new tool, HRDetect, to pinpoint tumors that display BRCA deficiency but don't harbor BRCA1/2 mutations. Evaluating their method in breast, ovarian, and pancreatic cancers, they identified patients whose tumors were potentially vulnerable to PARP inhibition but who didn't carry these mutations.
from Cancer via ola Kala on Inoreader http://ift.tt/2qMMnWd
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου